HomePage | Biosensors International Ltd

Spotlight TCT 2015
This year, LEADERS Free is selected as one of the leading featured Late Breaking Clinical Trials.
The primary endpoint of this Landmark Double-blind Randomized Controlled Trial will be presented by Philip Urban in the TCT Main Arena, Wednesday, 14 October
at 11:00 AM.
Biosensors International will also host a Lunch Symposium "Bleeding risk and 1-month DAPT: Can LEADERS Free shift the Paradigm?"
on Wednesday, 14 October
at 1:00 PM in the Presentation Theater 4.
BioMatrix NEOFLEX™
BioMatrix NeoFlex™ is the latest addition to the BioMatrix family of drug-eluting stents (DES).™
It features an enhanced catheter delivery system with a lower entry profile than its predecessor, so improving pushability, trackability and crossability. BioMatrix NeoFlex retains the same unique combination of abluminal biodegradable polymer coating, Biolimus A9™ and flexible platform which have made the BioMatrix family of DES so popular.

Spotlight BioFreedom™
PCI in High Bleeding Risk
(HBR) patients
With HBR patients, the challenge is to balance the ischemic risk versus the bleeding risk associated with long-term DAPT.
Drug-eluting stents (DES) require dual antiplatelet therapy (DAPT), to avoid stent thrombosis (ST). However, prolonged DAPT has been shown to increase the risk of bleeding in the general PCI population. Clinical data show that bleeding is associated with an increased risk of mortality.
High Bleeding Risk patients are at even greater risk.
First Quarter FY2016 Financial Results Webcast Monday, 3 August 2015
at 6pm Singapore time